Logo image
Back
Changes over time in risk factors for cardiovascular disease and use of Lipid‐lowering drugs in HIV‐Infected individuals and impact on myocardial infarction
Journal article   Open access   Peer reviewed

Changes over time in risk factors for cardiovascular disease and use of Lipid‐lowering drugs in HIV‐Infected individuals and impact on myocardial infarction

C. Sabin, A. D'Arminio Monforte, N. Friis-Moller, R. Weber, W. El-Sadr, P. Reiss, O. Kirk, P. Mercie, M. Law, S. De Wit, …
Clinical Infectious Diseases, Vol.46(7), pp.1101-1110
2008
DOI: https://doi.org/10.1086/528862
pdf
changes_over_time.pdfDownloadView
Published (Version of Record) Open Access
url
Link to Published Version *Subscription may be requiredView

Abstract

Background. Because of the known relationship between exposure to combination antiretroviral therapy and cardiovascular disease (CVD), it has become increasingly important to intervene against risk of CVD in human immunodeficiency virus (HIV)—infected patients. We evaluated changes in risk factors for CVD and the use of lipid-lowering therapy in HIV-infected individuals and assessed the impact of any changes on the incidence of myocardial infarction. Methods. The Data Collection on Adverse Events of Anti-HIV Drugs Study is a collaboration of 11 cohorts of HIV-infected patients that included follow-up for 33,389 HIV-infected patients from December 1999 through February 2006. Results. The proportion of patients at high risk of CVD increased from 35.3% during 1999–2000 to 41.3% during 2005–2006. Of 28,985 patients, 2801 (9.7%) initiated lipid-lowering therapy; initiation of lipid-lowering therapy was more common for those with abnormal lipid values and those with traditional risk factors for CVD (male sex, older age, higher body mass index [calculated as the weight in kilograms divided by the square of the height in meters], family and personal history of CVD, and diabetes mellitus). After controlling for these, use of lipid-lowering drugs became relatively less common over time. The incidence of myocardial infarction (0.32 cases per 100 person-years [PY]; 95% confidence interval [CI], 0.29–0.35 cases per 100 PY) appeared to remain stable. However, after controlling for changes in risk factors for CVD, the rate decreased over time (relative rate in 2003 [compared with 1999–2000], 0.73 cases per 100 PY [95% CI, 0.50–1.05 cases per 100 PY]; in 2004, 0.64 cases per 100 PY [95% CI, 0.44–0.94 cases per 100 PY]; in 2005–2006, 0.36 cases per 100 PY [95% CI, 0.24–0.56 cases per 100 PY]). Further adjustment for lipid levels attenuated the relative rates towards unity (relative rate in 2003 [compared with 1999–2000], 1.06 cases per 100 PY [95% CI, 0.63–1.77 cases per 100 PY]; in 2004, 1.02 cases per 100 PY [95% CI, 0.61–1.71 cases per 100 PY]; in 2005–2006, 0.63 cases per 100 PY [95% CI, 0.36–1.09 cases per 100 PY]). Conclusions. Although the CVD risk profile among patients in the Data Collection on Adverse Events of Anti-HIV Drugs Study has decreased since 1999, rates have remained relatively stable, possibly as a result of a more aggressive approach towards managing the risk of CVD.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

283 File views/ downloads
67 Record Views
44 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.66 HIV
1.66.1372 HIV Comorbidities
Web Of Science research areas
Immunology
Infectious Diseases
Microbiology
ESI research areas
Immunology
Logo image